Juno Therapeutics Gmbh

Tom Kowski

Kenneth Mayo Prentice

Paul Ken Kodama

Jeff D Smith

Mark J Gilbert

Christian Stemberger

He Li

Mirna Mujacic

Christopher Glen Ramsborg

Ryan P Larson

Pascal Beauchesne

Clinton Weber

Nathan K Yee

Kathryn Lindsay Pollock

Claire L Sutherland

Brian Christin

Valerie Odegard

Kedar Himanshu Dave

Mary Mallaney

Andrew W Walker

Thomas Schmidt

Ken Prentice

Nikolaus Sebastian Trede

Michael Gerard Covington

Richard James Getto, Jr

James Boyd Whitmore

Travis Beckett

Mima Mujacic

Samuel Charles Blackman

Nathaniel Chartrand

Nathaniel Lambert

Mel Davis-pickett

Provided herein are methods for assessing cell surface glycans, e.g., N-glycans, by assessing a sample of released surface glycans, and determining the presence, absence, or level of glycans present in the sample. Also provided are methods of assaying and/or evaluating a cell composition by assessing the cell surface glycan profile of the cell composition and comparing the profile to a reference sample. Methods for manufacturing and/or culturing a plurality of cell compositions having consistent surface glycan expression with low variability are also provided.

Methods for assessing cell surface glycosylation

Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

Determining toxicity risk in CAR T-cell therapy

Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion, activation, and/or survival, of a composition of cells such as a population of lymphocytes. In some aspects, the disclosure provides methods and reagents for the stimulation, survival, persistence, activation, or other effect of cell populations that involve binding of agents to a molecule on the cell surface.

Oligomeric particle reagents and methods of use thereof

Growing community of inventors

Seattle, WA, United States of America

Tom Kowski